サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1529796

ポリヌクレオチド注射剤の世界市場：市場規模、シェア・動向分析 - 用途別、最終用途別、地域別、セグメント別予測、2024～2030年

Polynucleotides Injectable Market Size, Share & Trends Analysis Report By Application (Eyes, Lips, Forehead, Jawline & Cheekbones), By End-use (MedSpas, Aesthetic & Cosmetic Centers), By Region, and Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 125 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
ポリヌクレオチド注射剤の世界市場：市場規模、シェア・動向分析 - 用途別、最終用途別、地域別、セグメント別予測、2024～2030年
出版日: 2024年07月18日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のポリヌクレオチド注射剤の市場規模は、2023年に1億1,150万米ドルに達し、2024～2030年にかけてCAGR 14.9%で成長すると予測されています。

バイオテクノロジーの技術進歩が主に市場を牽引しており、肌の若返り、個別化医療、研究開発（R&D）への投資に対する需要の高まりも市場を牽引しています。PMTA Journal誌が2024年3月に発表した記事によると、ポリヌクレオチド注射剤は、この包括的なレビューで検討されているように、皮膚、毛髪、その他の組織に対する有益な効果により、美容医療で脚光を浴びるようになった。

高度な肌の若返り治療に対する需要の高まりが、ポリヌクレオチド注射剤市場の主な促進要因です。小じわ、しわ、皮膚のたるみといった老化の兆候に対処するためのより効果的な解決策を個人が求めるにつれ、ポリヌクレオチドのような新規の注射治療への関心が急増しています。例えば、Dermatologic Therapy誌に掲載された最近の研究では、ポリヌクレオチド注射剤によって、30代から40代の患者の肌の色調、小じわ、肌の弾力性、潤いが改善したことが明らかになった。

個別化医療への注目が高まっていることも、市場の成長に寄与しています。ヘルスケアプロバイダーも患者も同様に、皮膚の若返りに対するカスタマイズされたアプローチを求めるようになり、ポリヌクレオチドの体内の自然なコラーゲン産生と細胞再生を刺激する能力は、ポリヌクレオチドを人気の選択肢としました。この動向は、特に個別化された美容治療に対する需要の高まりに顕著に表れており、今後も市場の拡大が見込まれています。

最後に、デジタル画像や自動注射システムなどの革新的な技術の統合が、ポリヌクレオチド注射剤市場をさらに促進しています。これらの進歩により、ポリヌクレオチド注射剤の精度、一貫性、安全性が向上し、ヘルスケアプロバイダーや患者にとってより魅力的なものとなった。美容産業が進化を続ける中、最先端技術を取り入れることは、ポリヌクレオチド注射剤市場の重要な促進要因であり続けると予想されます。例えば、2022年には、ロンドンのPulse Light Clinicが、肌の水分補給を著しく高め、弾力性を高め、天然のコラーゲン生成を刺激することで知られる革新的なポリヌクレオチド注入治療、PhilArt by Cromaを導入します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ポリヌクレオチド注射剤市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し
  • 市場力学
    • 市場の促進要因分析
    • 市場の抑制要因分析
  • ポリヌクレオチド注射剤市場分析ツール
    • 業界分析 - ポーターのファイブフォース分析
    • PESTEL分析

第4章 ポリヌクレオチド注射剤市場：用途の推定・動向分析

  • 用途市場シェア、2023年・2030年
  • セグメントダッシュボード
  • 世界のポリヌクレオチド注射剤市場、用途別展望
  • 市場規模・予測、動向分析、2018～2030年

第5章 ポリヌクレオチド注射剤市場：最終用途の推定・動向分析

  • 最終用途市場シェア、2023年・2030年
  • セグメントダッシュボード
  • 世界のポリヌクレオチド注射剤市場、最終用途別展望
  • 市場規模・予測、動向分析、2018～2030年

第6章 ポリヌクレオチド注射剤市場：地域の推定・動向分析

  • 地域別市場シェア分析、2023年・2030年
  • 地域別市場ダッシュボード
  • 世界の地域別市場スナップショット
  • 市場規模・予測、動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要代理店およびチャネルパートナーリスト
    • 主要顧客
    • 主要企業の市場シェア分析、2023年
    • PHARMA RESEARCH
    • BIOPLUS CO., LTD.
    • LG Chem
    • AMEELA
    • Mastelli
    • Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
    • Promoitalia Laboratories
    • Fox Pharma
    • BR Pharm
    • DermFocus
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 10 Mexico polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 13 Europe polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Germany polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 15 Germany polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 17 UK polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 19 France polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 21 Italy polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 23 Spain polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Denmark polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 25 Denmark polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Sweden polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 27 Sweden polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 29 Norway polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 33 China polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 34 China polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Japan polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 36 Japan polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 37 India polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 38 India polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 40 South Korea polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Australia polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 42 Australia polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Thailand polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 44 Thailand polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 46 Latin America polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Brazil polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 48 Brazil polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Argentina polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 50 Argentina polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 51 MEA polynucleotides injectables market, by region, 2018 - 2030 (USD Million)
  • Table 52 MEA polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 53 MEA polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 54 South Africa polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Africa polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 58 UAE polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 59 UAE polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Kuwait polynucleotides injectables market, by application, 2018 - 2030 (USD Million)
  • Table 61 Kuwait polynucleotides injectables market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Polynucleotides Injectable market: market outlook
  • Fig. 14 Polynucleotides Injectable competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Polynucleotides Injectable market driver impact
  • Fig. 20 Polynucleotides Injectable market restraint impact
  • Fig. 21 Polynucleotides Injectable market strategic initiatives analysis
  • Fig. 22 Polynucleotides Injectable market: application movement analysis
  • Fig. 23 Polynucleotides Injectable market: application outlook and key takeaways
  • Fig. 24 Eyes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Lips market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Forehead market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Jawline & cheekbones market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Polynucleotides Injectable market: end-use movement analysis
  • Fig. 30 Polynucleotides Injectable market: end-use outlook and key takeaways
  • Fig. 31 MedSpas market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Aesthetic & Cosmetic centers market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 33 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Global Polynucleotides Injectable market: Regional movement analysis
  • Fig. 35 Global Polynucleotides Injectable market: Regional outlook and key takeaways
  • Fig. 36 Global Polynucleotides Injectable market share and leading players
  • Fig. 37 North America market share and leading players
  • Fig. 38 Europe market share and leading players
  • Fig. 39 Asia Pacific market share and leading players
  • Fig. 40 Latin America market share and leading players
  • Fig. 41 Middle East & Africa market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. key country dynamics
  • Fig. 46 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Canada key country dynamics
  • Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico key country dynamics
  • Fig. 50 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 UK key country dynamics
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Germany key country dynamics
  • Fig. 56 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 France key country dynamics
  • Fig. 58 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Italy key country dynamics
  • Fig. 60 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Spain key country dynamics
  • Fig. 62 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Denmark key country dynamics
  • Fig. 64 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Sweden key country dynamics
  • Fig. 66 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Norway key country dynamics
  • Fig. 68 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 China key country dynamics
  • Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan key country dynamics
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 India key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Australia key country dynamics
  • Fig. 78 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea key country dynamics
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Thailand key country dynamics
  • Fig. 82 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Brazil key country dynamics
  • Fig. 86 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Argentina key country dynamics
  • Fig. 88 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 South Africa key country dynamics
  • Fig. 92 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Saudi Arabia key country dynamics
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 UAE key country dynamics
  • Fig. 96 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Kuwait key country dynamics
  • Fig. 98 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Market share of key market players- Polynucleotides Injectable market
目次
Product Code: GVR-4-68040-361-6

Polynucleotides Injectable Market Trends

The global polynucleotides injectable market size was estimated at USD 111.5 million in 2023 and is projected to grow at a CAGR of 14.9% from 2024 to 2030.Technological advancements in biotechnology primarily drive the market, as do the growing demand for skin rejuvenation, personalized medicine, and investments in research and development (R&D). According to an article published by PMTA Journal in March 2024, polynucleotide injections gained prominence in aesthetic medicine due to their beneficial effects on skin, hair, and other tissues, as explored in this comprehensive review.

The growing demand for advanced skin rejuvenation treatments is a primary driver of the polynucleotides injectable market. As individuals seek more effective solutions to address signs of aging, such as fine lines, wrinkles, and skin laxity, the interest in novel injectable treatments such as polynucleotides has surged. For instance, a recent study published in the journal Dermatologic Therapy found that polynucleotide injections improved skin tone, fine lines, skin elasticity, and hydration in patients in their 30s and 40s.

The increasing focus on personalized medicine also contributed to the growth of the market. As healthcare providers and patients alike seek customized approaches to skin rejuvenation, polynucleotides' ability to stimulate the body's natural collagen production and cellular regeneration made them a popular choice. This trend is particularly evident in the rising demand for personalized aesthetic treatments, which is expected to continue expanding the market.

Finally, integrating innovative technologies, such as digital imaging and automated injection systems, has further propelled the polynucleotides injectables market. These advancements improved polynucleotide injections' precision, consistency, and safety, making them more appealing to healthcare providers and patients. As the aesthetic industry continues to evolve, incorporating cutting-edge technologies is expected to remain a vital driver of the polynucleotide injectable market. For instance, in 2022, Pulse Light Clinic in London is introducing PhilArt by Croma, an innovative polynucleotide injection treatment recognized for significantly enhancing skin hydration, boosting elasticity, and stimulating natural collagen production - a pioneering advancement in skin rejuvenation.

Global Polynucleotides Injectable Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global polynucleotides injectable market report based on application, end-use, and region.

  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Eyes
  • Lips
  • Forehead
  • Jawline & Cheekbones
  • Others
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • MedSpas
  • Aesthetic & Cosmetic Centers
  • Hospitals
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Polynucleotides Injectable Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements
      • 3.2.1.2. Growing demand for skin rejuvenation
      • 3.2.1.3. Shifting focus towards regenerative aesthetics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited access to the treatments
  • 3.3. Polynucleotides Injectable Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Polynucleotides Injectable Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Polynucleotides Injectable Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Eyes
      • 4.4.1.1. Eyes market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Lips
      • 4.4.2.1. Lips market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Forehead
      • 4.4.3.1. Forehead market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Jawline & Cheekbones
      • 4.4.4.1. Jawline & Cheekbones market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Polynucleotides Injectable Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Polynucleotides Injectable Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. MedSpas
      • 5.4.1.1. MedSpas market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Aesthetic & Cosmetic Centers
      • 5.4.2.1. Aesthetic & cosmetic centers market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hospitals
      • 5.4.3.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Polynucleotides Injectable Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 6.5. North America
    • 6.5.1. North America
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Denmark
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Norway
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. PHARMA RESEARCH
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Others benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. BIOPLUS CO., LTD.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Others benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. LG Chem
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Others benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. AMEELA
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Others benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Mastelli
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Others benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Others benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Promoitalia Laboratories
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Others benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Fox Pharma
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Others benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. BR Pharm
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Others benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. DermFocus
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Others benchmarking
      • 7.3.13.4. Strategic initiatives